Anaplastic astrocytoma

Current Treatment Options in Neurology

Volumn 15, Issue 3, 2013, Pages 302-315

  Grimm, Sean A ^a   Pfiffner, Thomas J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anaplastic astrocytoma; Bevacizumab; Chemotherapy; Malignant glioma; Molecular markers; Radiotherapy; Temozolomide; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID; DEXAMETHASONE; ETIRACETAM; IRINOTECAN; LOMUSTINE; LOW MOLECULAR WEIGHT HEPARIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VALPROIC ACID; VINCRISTINE; WARFARIN;

ABDOMINAL PAIN; ACUTE LEUKEMIA; AGGRESSION; ANEMIA; ARTICLE; ASTHENIA; AUTONOMIC NEUROPATHY; AVASCULAR NECROSIS; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN RADIATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COGNITIVE DEFECT; CONSTIPATION; CORTICOSTEROID INDUCED MYOPATHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEEP VEIN THROMBOSIS; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DROWSINESS; DRUG CLEARANCE; DRUG COST; DRUG DOSE INCREASE; EPISTAXIS; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; GLAUCOMA; GLIOBLASTOMA; HAIR LOSS; HEADACHE; HICCUP; HUMAN; HYPERACTIVITY; HYPERSOMNIA; HYPERTENSION; ILEUS; INFUSION RELATED REACTION; INSOMNIA; IRRITABILITY; LEUKOENCEPHALOPATHY; LEUKOPENIA; LUNG FIBROSIS; LUNG INFILTRATE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROIMAGING; NEUROPATHIC PAIN; NEUTROPENIA; NOCTURIA; OLIGODENDROGLIOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL NEUROPATHY; PNEUMOCYSTOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; PSYCHOSIS; RADIATION NECROSIS; REOPERATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEREOTACTIC RADIOSURGERY; SUICIDAL IDEATION; THROMBOCYTOPENIA; TREMOR; TUMOR GROWTH; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

EID: 84878283401     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0228-7     Document Type: Article

References (80)

1. Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol. 2007;63(1):72-80.
2. Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF. Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. J Neurooncol. 2012;110(2):227-35.
3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14 Suppl 5:v1-49.
4. Prados MD, Gutin PH, Phillips TL, Wara WM, Larson DA, Sneed PK, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys. 1992;23(1):3-8.
5. Mechtler L. Neuroimaging in neuro-oncology. Neurol Clin. 2009;27(1):171-201. ix.
6. Thomas TL, Stolley PD, Stemhagen A, Fontham ET, Bleecker ML, Stewart PA, et al. Brain tumor mortality risk among men with electrical and electronics jobs: a case-control study. J Natl Cancer Inst. 1987;79(2):233-8.
7. Thomas TL, Stewart PA, Stemhagen A, Correa P, Norman SA, Bleecker ML, et al. Risk of astrocytic brain tumors associated with occupational chemical exposures. A case-referent study. Scand J Work Environ Health. 1987;13(5):417-23.
8. Heineman EF, Cocco P, Gomez MR, Dosemeci M, Stewart PA, Hayes RB, et al. Occupational exposure to chlorinated aliphatic hydrocarbons and risk of astrocytic brain cancer. Am J Ind Med. 1994;26(2):155-69.
9. Coble JB, Dosemeci M, Stewart PA, Blair A, Bowman J, Fine HA, et al. Occupational exposure to magnetic fields and the risk of brain tumors. Neuro Oncol. 2009;11(3):242-9.
10. Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res. 1998;17(4):479-82.
11. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet. 2003;361(9354):323-31.
12. Moenninghoff C, Maderwald S, Theysohn JM, Kraff O, Ladd ME, El Hindy N, et al. Imaging of adult astrocytic brain tumours with 7 T MRI: preliminary results. Eur Radiol. 2010;20(3):704-13.
13. Jenkinson MD, Du Plessis DG, Walker C, Smith TS. Advanced MRI in the management of adult gliomas. Br J Neurosurg. 2007;21(6):550-61.
14. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol. 2005;6(3):167-75.
15. Astrakas LG, Zurakowski D, Tzika AA, Zarifi MK, Anthony DC, De Girolami U, et al. Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res. 2004;10(24):8220-8.
16. Walker C, Baborie A, Crooks D, Wilkins S, Jenkinson MD. Biology, genetics and imaging of glial cell tumours. Br J Radiol. 2011;84(Spec No 2):S90-106.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
18. Sarkar C, Jain A, Suri V. Current concepts in the pathology and genetics of gliomas. Indian J Cancer. 2009;46(2):108-19.
19. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer. 1992;66(2):373-85.
20. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol. 1993;52(6):609-18.
21. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol. 1994;87(1):47-54.
22. Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061- 8.
23. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-12.
24. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep. 2011;11(3):291-7. An excellent review of the genomic profiles of glioma.
25. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683-710.
26. Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, et al. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol. 2011;104(1):253-9.
27. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-73.
28. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-4.
29. Gilbert MR. RTOG 0525: a randomized Phase III trial comparing standard adjuvant temozolomide with a dose-dense schedule in newly diagnosed glioblastoma. J Clin Oncol. 2011;29(suppl).
30. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
31. Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012;110(3):325-33.
32. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874-80.
33. Gupta R, Webb-Myers R, Flanagan S, Buckland ME. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol. 2011;64(10):835-44. A comprehensive review of isocitrate dehydrogenase mutations in diffuse gliomas.
34. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-73.
35. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487-94.
36. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-44.
37. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-18. Analysis of the role of isocitrate dehydrogenase 1 mutation status and prognosis of patients with anaplastic astrocytoma and glioblastoma.
38. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886-93.
39. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, G. Levetiracetam Monotherapy Study. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402-8.
40. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-30.
41. DeAngelis LM, Posner JB, Posner JB. Neurologic complications of cancer. Contemporary neurology series. 2nd ed. Oxford: Oxford University; 2009.
42. Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol. 2012;14 Suppl 4:iv73-80.
43. Anderson F, Huang W, Sullivan C, et al. The continuing risk of venous thromboembolism following operation for glioma: findings from teh Glioma Outcomes Project. Throm Hemost. 2001;86(Suppl).
44. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997;33(10):1592-6.
45. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8(9):1959-65.
46. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.
47. Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012;106(1):121-5.
48. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993;43(6):1111-4.
49. Nicolas JM, Collart P, Gerin B, Mather G, Trager W, Levy R, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos. 1999;27(2):250-4.
50. Hall WA, Galicich W, Bergman T, Truwit CL. 3-Tesla intraoperative MR imaging for neurosurgery. J Neurooncol. 2006;77(3):297-303.
51. Liang D, Schulder M. The role of intraoperative magnetic resonance imaging in glioma surgery. Surg Neurol Int. 2012;3 Suppl 4:S320-7.
52. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12(11):997-1003.
53. Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol. 1978;17(6):475-84.
54. Douglas BG, Worth AJ. Superfractionation in glioblastoma multiforme-results of a phase II study. Int J Radiat Oncol Biol Phys. 1982;8(10):1787-94.
55. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30(9):907-11.
56. Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys. 1979;5(10):1733-40.
57. Shapiro WR, Green SB, Burger PC, Mahaley Jr MS, Selker RG, VanGilder JC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989;71(1):1-9.
58. Walker MD, Alexander Jr E, Hunt WE, MacCarty CS, Mahaley Jr MS, Mealey Jr J, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333-43.
59. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5(10):1725-31.
60. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16(6):1405-9.
61. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 2005;63(1):47-55.
62. Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;49(1):71-7.
63. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245(11):695-708.
64. Freeman JE, Johnston PG, Voke JM. Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukaemia. Br Med J. 1973;4(5891):523-5.
65. Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg. 1979;50(5):624-8.
66. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360(9343):1361-8.
67. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.
68. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011-8.
69. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-61.
70. Fink J, Born D, Chamberlain MC. Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol. 2011;12(3):240-52.
71. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192-7.
72. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-15. Prospective study that demonstrated that temozolomide chemotherapy alone is equivalent to radiotherapy in patients with malignant astrocytoma.
73. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17(9):2762-71.
74. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051-7. Prospective study demonstrating that continuous dose-intense temozolomide is an effective treatment option for some patients with recurrent anaplastic astrocytoma.
75. Desjardins A, Reardon DA, Herndon 2nd JE, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14(21):7068-73.
76. Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011;13(10):1143-50. Prospective study demonstrating the improvement in quality of life and neurologic function in anaplastic astrocytoma patients treated with bevacizuamb.
77. Adkison JB, Tome W, Seo S, Richards GM, Robins HI, Rassmussen K, et al. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(3):835-41.
78. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28(18):3048-53.
79. Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol. 2010;12(4):321-33. An excellent review of treatment options for patients with recurrent malignant glioma.
80. Guo C, Pirozzi CJ, Lopez GY, Yan H. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol. 2011;24(6):648-52.